IBBQ Invesco Nasdaq Biotechnology ETF
36.57
-0.23 (-0.62%)
Kurs vom Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Vorheriger Schlusskurs | 36.80 | Tagesspanne | 36.42 – 36.78 |
| 52-Wochen-Spanne | 23.32 – 36.84 | Volumen | 21.57K |
| Durchschn. Volumen | 24.80K | AUM | $95.8M (Aug 27, 2026) |
| Kostenquote | 0.19% | Rendite (TTM) | 0.70% |
| NAV | 36.71 | Aufgeld/Abschlag | -0.38% indikativ |
| Auflegung | Jun 11, 2021 | Positionen | 251 |
| Anbieter | Invesco | Börse | NASDAQ |
| Kategorie | Biotech | Abgebildeter Index | In den Quelldaten nicht angegeben |
| CUSIP | 46138G599 | ISIN | US46138G5999 |
| Management | In den Quelldaten nicht angegeben | ||
Über diesen ETF
The Invesco Nasdaq Biotechnology ETF (IBBQ) seeks to mirror the investment performance of the Nasdaq Biotechnology Index. To achieve this, the Fund generally dedicates at least 90% of its total capital to the securities that make up this benchmark index. The underlying Index itself is specifically designed to gauge the returns of biotechnology and pharmaceutical companies whose shares are publicly traded on the Nasdaq Stock Market. Both the ETF and its corresponding Index undergo a yearly review and update of their composition each December, and their weightings are adjusted quarterly in March, June, September, and December.
Beschreibung vom Fondsdatenanbieter · Profil per Aug 27, 2026.
Kurschart
Tägliche Schlusskurse (Kursrendite, nicht Gesamtrendite). Die Vergleichslinien sind auf die prozentuale Veränderung ab dem Beginn des Zeitraums normiert. Quelle: Financial Modeling Prep.
Wertentwicklung
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Auflegung* | |
|---|---|---|---|---|---|---|---|---|---|
| Kursrendite | +12.80% | +23.88% | +21.98% | +28.77% | +55.55% | +21.27% | +6.39% | — | +7.10% |
| Gesamtrendite | +12.80% | +24.01% | +22.23% | +29.04% | +57.02% | +22.38% | +7.36% | — | +8.05% |
* Annualisiert. Die Gesamtrendite verwendet die dividendenbereinigte Kursreihe (Ausschüttungen reinvestiert); die Kursrendite verwendet unbereinigte Schlusskurse. Wertentwicklung per Aug 26, 2026. Vergangene Wertentwicklungen sind kein verlässlicher Indikator für künftige Ergebnisse.
Gebühren
| Nettokostenquote | 0.19% | Jährliche Kosten einer Anlage von 10.000 $ | $19.00 |
Nur zur Veranschaulichung: Kostenquote × 10.000 $. Handelskosten, Geld-Brief-Spannen, Steuern und Wertänderungen sind nicht enthalten. Details zu Brutto- und Nettokostenquote sowie etwaige Gebührenbefreiungen sind im Prospekt aufgeführt.
Positionen
Positionen per Aug 22, 2026 — Portfolio-Meldedatum des Datenanbieters; die Positionen sind keine Echtzeit-Bestände. 260 Zeilen in der Datenbank.
| # | Position | Ticker | Gewichtung | Aktien | Marktwert |
|---|---|---|---|---|---|
| 1 | Amgen Inc | AMGN | 8.67% | 18.29K | $7.9M |
| 2 | Vertex Pharmaceuticals Inc | VRTX | 8.14% | 13.78K | $7.4M |
| 3 | Gilead Sciences Inc | GILD | 7.19% | 45.85K | $6.6M |
| 4 | Regeneron Pharmaceuticals Inc | REGN | 5.48% | 6.07K | $5.0M |
| 5 | Moderna Inc | MRNA | 3.40% | 23.32K | $3.1M |
| 6 | Revolution Medicines Inc | RVMD | 2.89% | 12.50K | $2.6M |
| 7 | Illumina Inc | ILMN | 2.07% | 8.90K | $1.9M |
| 8 | Biogen Inc | BIIB | 2.03% | 8.68K | $1.9M |
| 9 | Alnylam Pharmaceuticals Inc | ALNY | 1.97% | 7.86K | $1.8M |
| 10 | Argenx SE | ARGNF | 1.83% | 1.61K | $1.7M |
| 11 | Insmed Inc | INSM | 1.74% | 12.75K | $1.6M |
| 12 | Royalty Pharma PLC | RPRX | 1.73% | 26.06K | $1.6M |
| 13 | Roivant Sciences Ltd | ROIV | 1.70% | 42.28K | $1.6M |
| 14 | Incyte Corp | INCY | 1.63% | 11.75K | $1.5M |
| 15 | Guardant Health Inc | GH | 1.43% | 7.78K | $1.3M |
| 16 | United Therapeutics Corp | UTHR | 1.42% | 2.50K | $1.3M |
| 17 | Viatris Inc | VTRS | 1.21% | 68.45K | $1.1M |
| 18 | Medpace Holdings Inc | MEDP | 1.13% | 1.69K | $1.0M |
| 19 | Bridgebio Pharma Inc | BBIO | 1.04% | 11.51K | $955.0K |
| 20 | Ascendis Pharma A/S | ASND | 1.01% | 3.62K | $921.4K |
| 21 | Jazz Pharmaceuticals PLC | JAZZ | 1.00% | 3.68K | $914.7K |
| 22 | Neurocrine Biosciences Inc | NBIX | 0.99% | 5.91K | $903.7K |
| 23 | Exelixis Inc | EXEL | 0.87% | 14.78K | $793.7K |
| 24 | BioMarin Pharmaceutical Inc | BMRN | 0.84% | 11.35K | $768.3K |
| 25 | BioNTech SE | BNTX | 0.83% | 6.84K | $758.4K |
| 26 | Halozyme Therapeutics Inc | HALO | 0.81% | 6.97K | $739.3K |
| 27 | Arrowhead Pharmaceuticals Inc | ARWR | 0.79% | 8.27K | $723.6K |
| 28 | BeOne Medicines Ltd | ONC | 0.79% | 1.95K | $720.6K |
| 29 | Madrigal Pharmaceuticals Inc | MDGL | 0.76% | 1.35K | $699.7K |
| 30 | Tempus AI Inc | TEM | 0.75% | 10.26K | $683.6K |
| 31 | Axsome Therapeutics Inc | AXSM | 0.69% | 3.03K | $630.3K |
| 32 | Sanofi SA | SNY | 0.67% | 13.67K | $617.1K |
| 33 | Cytokinetics Inc | CYTK | 0.67% | 7.97K | $614.8K |
| 34 | Praxis Precision Medicines Inc | PRAX | 0.65% | 1.63K | $593.9K |
| 35 | Kymera Therapeutics Inc | KYMR | 0.64% | 4.84K | $587.8K |
| 36 | Krystal Biotech Inc | KRYS | 0.64% | 1.74K | $586.1K |
| 37 | Ionis Pharmaceuticals Inc | IONS | 0.62% | 9.72K | $570.9K |
| 38 | Protagonist Therapeutics Inc | PTGX | 0.62% | 3.79K | $570.5K |
| 39 | Summit Therapeutics Inc | SMMT | 0.62% | 45.62K | $567.1K |
| 40 | Spyre Therapeutics Inc | SYRE | 0.60% | 5.11K | $550.4K |
| 41 | Immunovant Inc | IMVT | 0.58% | 12.06K | $535.1K |
| 42 | Crinetics Pharmaceuticals Inc | CRNX | 0.57% | 6.19K | $524.5K |
| 43 | Vaxcyte Inc | PCVX | 0.57% | 8.48K | $520.4K |
| 44 | Twist Bioscience Corp | TWST | 0.54% | 3.65K | $498.0K |
| 45 | Apogee Therapeutics Inc | APGE | 0.54% | 3.63K | $489.7K |
| 46 | ImmunityBio Inc | IBRX | 0.53% | 61.55K | $482.6K |
| 47 | Alkermes PLC | ALKS | 0.51% | 9.79K | $470.2K |
| 48 | Rhythm Pharmaceuticals Inc | RYTM | 0.48% | 4.04K | $439.8K |
| 49 | 10X Genomics Inc | TXG | 0.48% | 6.88K | $439.1K |
| 50 | Caris Life Sciences Inc | CAI | 0.45% | 16.62K | $408.5K |
| 51 | CG oncology Inc | CGON | 0.44% | 5.18K | $401.9K |
| 52 | Abivax SA | ABVX | 0.44% | 3.40K | $401.9K |
| 53 | Scholar Rock Holding Corp | SRRK | 0.43% | 7.06K | $389.8K |
| 54 | Oruka Therapeutics Inc | ORKA | 0.41% | 3.55K | $372.1K |
| 55 | Cogent Biosciences Inc | COGT | 0.39% | 10.04K | $354.4K |
| 56 | Travere Therapeutics Inc | TVTX | 0.38% | 5.46K | $351.8K |
| 57 | Mirum Pharmaceuticals Inc | MIRM | 0.38% | 3.58K | $348.0K |
| 58 | PTC Therapeutics Inc | PTCT | 0.38% | 4.88K | $343.8K |
| 59 | Ligand Pharmaceuticals Inc | LGND | 0.37% | 1.19K | $341.4K |
| 60 | Xenon Pharmaceuticals Inc | XENE | 0.37% | 5.68K | $339.1K |
| 61 | Amneal Pharmaceuticals Inc | AMRX | 0.37% | 18.75K | $335.6K |
| 62 | CRISPR Therapeutics AG | CRSP | 0.36% | 5.67K | $329.3K |
| 63 | Erasca Inc | ERAS | 0.34% | 18.27K | $312.1K |
| 64 | ACADIA Pharmaceuticals Inc | ACAD | 0.32% | 10.06K | $292.1K |
| 65 | Definium Therapeutics Inc | DFTX | 0.32% | 6.41K | $291.0K |
| 66 | Edgewise Therapeutics Inc | EWTX | 0.30% | 6.33K | $274.1K |
| 67 | Indivior Pharmaceuticals Inc | INDV | 0.30% | 7.17K | $270.8K |
| 68 | Amylyx Pharmaceuticals Inc | AMLX | 0.28% | 6.55K | $259.7K |
| 69 | Dyne Therapeutics Inc | DYN | 0.28% | 9.72K | $252.5K |
| 70 | Relay Therapeutics Inc | RLAY | 0.27% | 12.60K | $248.3K |
| 71 | Adaptive Biotechnologies Corp | ADPT | 0.26% | 9.41K | $239.5K |
| 72 | Iovance Biotherapeutics Inc | IOVA | 0.26% | 26.26K | $236.1K |
| 73 | Denali Therapeutics Inc | DNLI | 0.25% | 9.32K | $232.5K |
| 74 | Structure Therapeutics Inc | GPCR | 0.25% | 4.59K | $231.7K |
| 75 | Kiniksa Pharmaceuticals International Plc | KNSA | 0.23% | 2.73K | $214.3K |
| 76 | Enliven Therapeutics Inc | ELVN | 0.23% | 3.58K | $211.0K |
| 77 | AbCellera Biologics Inc | ABCL | 0.23% | 17.95K | $207.7K |
| 78 | Ideaya Biosciences Inc | IDYA | 0.22% | 5.16K | $201.8K |
| 79 | Tango Therapeutics Inc | TNGX | 0.22% | 8.50K | $199.8K |
| 80 | GRAIL Inc | GRAL | 0.22% | 2.53K | $197.0K |
| 81 | Veracyte Inc | VCYT | 0.21% | 4.68K | $195.7K |
| 82 | Newamsterdam Pharma Co NV | NAMS | 0.21% | 6.88K | $191.0K |
| 83 | Arcutis Biotherapeutics Inc | ARQT | 0.20% | 7.36K | $186.6K |
| 84 | MBX Biosciences Inc | MBX | 0.20% | 2.80K | $185.8K |
| 85 | Tarsus Pharmaceuticals Inc | TARS | 0.20% | 2.53K | $181.0K |
| 86 | uniQure NV | QURE | 0.20% | 3.69K | $180.6K |
| 87 | Disc Medicine Inc | IRON | 0.19% | 2.25K | $177.5K |
| 88 | Beam Therapeutics Inc | BEAM | 0.19% | 6.06K | $172.0K |
| 89 | Alumis Inc | ALMS | 0.18% | 7.25K | $165.7K |
| 90 | Nurix Therapeutics Inc | NRIX | 0.18% | 6.08K | $164.6K |
| 91 | Supernus Pharmaceuticals Inc | SUPN | 0.18% | 3.40K | $161.5K |
| 92 | AtaiBeckley Inc | ATAI | 0.18% | 21.65K | $160.7K |
| 93 | Precigen Inc | PGEN | 0.17% | 20.96K | $155.9K |
| 94 | Trevi Therapeutics Inc | TRVI | 0.17% | 8.36K | $152.5K |
| 95 | Pharvaris NV | PHVS | 0.16% | 4.11K | $149.4K |
| 96 | Genmab A/S | GMAB | 0.16% | 4.45K | $148.7K |
| 97 | Ultragenyx Pharmaceutical Inc | RARE | 0.16% | 5.80K | $146.8K |
| 98 | Kodiak Sciences Inc | KOD | 0.16% | 3.67K | $146.2K |
| 99 | BioCryst Pharmaceuticals Inc | BCRX | 0.16% | 14.93K | $144.2K |
| 100 | Ocular Therapeutix Inc | OCUL | 0.16% | 12.86K | $142.7K |
| 101 | Rapport Therapeutics Inc | RAPP | 0.15% | 2.81K | $134.6K |
| 102 | UroGen Pharma Ltd | URGN | 0.15% | 2.86K | $133.8K |
| 103 | ADMA Biologics Inc | ADMA | 0.15% | 13.62K | $132.9K |
| 104 | Vera Therapeutics Inc | VERA | 0.14% | 4.21K | $131.5K |
| 105 | Aurinia Pharmaceuticals Inc | AUPH | 0.14% | 7.57K | $130.8K |
| 106 | Harmony Biosciences Holdings Inc | HRMY | 0.14% | 3.40K | $129.3K |
| 107 | Vericel Corp | VCEL | 0.14% | 3.01K | $126.7K |
| 108 | Mineralys Therapeutics Inc | MLYS | 0.14% | 4.85K | $124.9K |
| 109 | Novocure Ltd | NVCR | 0.13% | 6.82K | $121.2K |
| 110 | Sarepta Therapeutics Inc | SRPT | 0.13% | 6.20K | $119.2K |
| 111 | Agios Pharmaceuticals Inc | AGIO | 0.13% | 3.50K | $117.9K |
| 112 | Xencor Inc | XNCR | 0.13% | 4.36K | $117.7K |
| 113 | Zenas Biopharma Inc | ZBIO | 0.13% | 3.70K | $117.0K |
| 114 | GH Research PLC | GHRS | 0.13% | 4.04K | $115.8K |
| 115 | Stoke Therapeutics Inc | STOK | 0.13% | 3.65K | $114.7K |
| 116 | Zymeworks Inc | ZYME | 0.12% | 4.30K | $114.2K |
| 117 | Compass Pathways Plc | CMPS | 0.12% | 7.83K | $108.3K |
| 118 | Septerna Inc | SEPN | 0.12% | 2.64K | $107.7K |
| 119 | Legend Biotech Corp | LEGN | 0.12% | 4.95K | $105.3K |
| 120 | Personalis Inc | PSNL | 0.11% | 6.16K | $103.9K |
| 121 | Taysha Gene Therapies Inc | TSHA | 0.11% | 16.89K | $103.2K |
| 122 | Recursion Pharmaceuticals Inc | RXRX | 0.11% | 30.83K | $103.0K |
| 123 | ANI Pharmaceuticals Inc | ANIP | 0.11% | 1.33K | $102.9K |
| 124 | Syndax Pharmaceuticals Inc | SNDX | 0.11% | 5.20K | $102.7K |
| 125 | Intellia Therapeutics Inc | NTLA | 0.11% | 8.21K | $102.1K |
| 126 | Fortrea Holdings Inc | FTRE | 0.11% | 5.57K | $101.3K |
| 127 | AnaptysBio Inc | ANAB | 0.11% | 1.72K | $97.5K |
| 128 | Eton Pharmaceuticals Inc | ETON | 0.10% | 1.60K | $96.0K |
| 129 | Immunocore Holdings PLC | IMCR | 0.10% | 2.61K | $94.7K |
| 130 | Maze Therapeutics Inc | MAZE | 0.10% | 3.26K | $94.3K |
| 131 | Bicara Therapeutics Inc | BCAX | 0.10% | 3.86K | $94.1K |
| 132 | Harrow Inc | HROW | 0.10% | 2.20K | $92.6K |
| 133 | Vir Biotechnology Inc | VIR | 0.10% | 9.92K | $91.4K |
| 134 | Innoviva Inc | INVA | 0.10% | 4.34K | $91.1K |
| 135 | Tyra Biosciences Inc | TYRA | 0.10% | 3.50K | $90.0K |
| 136 | Xeris Biopharma Holdings Inc | XERS | 0.10% | 10.16K | $87.4K |
| 137 | First Tracks Biotherapeutics Inc | TRAX | 0.09% | 2.05K | $85.9K |
| 138 | Absci Corp | ABSI | 0.09% | 9.17K | $85.1K |
| 139 | Inhibrx Biosciences Inc | INBX | 0.09% | 853 | $84.6K |
| 140 | ORIC Pharmaceuticals Inc | ORIC | 0.09% | 6.09K | $84.5K |
| 141 | Novavax Inc | NVAX | 0.09% | 9.67K | $81.4K |
| 142 | ArriVent Biopharma Inc | AVBP | 0.09% | 2.75K | $80.1K |
| 143 | Omeros Corp | OMER | 0.09% | 4.26K | $79.4K |
| 144 | MeiraGTx Holdings plc | MGTX | 0.09% | 5.44K | $79.1K |
| 145 | Alvotech SA | ALVO | 0.09% | 18.35K | $78.4K |
| 146 | MannKind Corp | MNKD | 0.08% | 18.16K | $77.4K |
| 147 | Cullinan Therapeutics Inc | CGEM | 0.08% | 3.61K | $77.2K |
| 148 | Monte Rosa Therapeutics Inc | GLUE | 0.08% | 4.96K | $73.2K |
| 149 | Vor BioPharma Inc | VOR | 0.08% | 3.17K | $73.2K |
| 150 | Maravai LifeSciences Holdings Inc | MRVI | 0.08% | 8.67K | $71.9K |
| 151 | Corvus Pharmaceuticals Inc | CRVS | 0.08% | 4.93K | $70.7K |
| 152 | Replimune Group Inc | REPL | 0.07% | 4.86K | $68.2K |
| 153 | Savara Inc | SVRA | 0.07% | 12.04K | $66.1K |
| 154 | Janux Therapeutics Inc | JANX | 0.07% | 3.58K | $61.9K |
| 155 | Sana Biotechnology Inc | SANA | 0.07% | 16.36K | $61.2K |
| 156 | Kura Oncology Inc | KURA | 0.07% | 5.21K | $61.0K |
| 157 | Wave Life Sciences Inc | WVE | 0.06% | 11.31K | $59.4K |
| 158 | Castle Biosciences Inc | CSTL | 0.06% | 1.78K | $58.7K |
| 159 | Geron Corp | GERN | 0.06% | 37.70K | $58.4K |
| 160 | Grifols SA | GRFS | 0.06% | 7.17K | $57.3K |
| 161 | Design Therapeutics Inc | DSGN | 0.06% | 3.66K | $57.0K |
| 162 | Ardelyx Inc | ARDX | 0.06% | 14.53K | $56.7K |
| 163 | Amphastar Pharmaceuticals Inc | AMPH | 0.06% | 2.59K | $56.1K |
| 164 | Olema Pharmaceuticals Inc | OLMA | 0.06% | 5.13K | $55.9K |
| 165 | Arbutus Biopharma Corp | ABUS | 0.06% | 11.60K | $55.3K |
| 166 | Pacira BioSciences Inc | PCRX | 0.06% | 2.31K | $55.1K |
| 167 | Mesoblast Ltd | MESO | 0.06% | 3.07K | $53.6K |
| 168 | Candel Therapeutics Inc | CADL | 0.06% | 4.31K | $53.3K |
| 169 | Solid Biosciences Inc | SLDB | 0.06% | 5.80K | $52.8K |
| 170 | Collegium Pharmaceutical Inc | COLL | 0.06% | 1.90K | $52.2K |
| 171 | Aclaris Therapeutics Inc | ACRS | 0.06% | 8.21K | $52.0K |
| 172 | Theravance Biopharma Inc | TBPH | 0.06% | 3.04K | $51.4K |
| 173 | Zai Lab Ltd | ZLAB | 0.06% | 1.95K | $50.7K |
| 174 | Annexon Inc | ANNX | 0.05% | 9.64K | $49.9K |
| 175 | 4D Molecular Therapeutics Inc | FDMT | 0.05% | 3.07K | $49.5K |
| 176 | Rigel Pharmaceuticals Inc | RIGL | 0.05% | 1.08K | $48.9K |
| 177 | Aura Biosciences Inc | AURA | 0.05% | 6.08K | $47.3K |
| 178 | Phibro Animal Health Corp | PAHC | 0.05% | 1.24K | $43.7K |
| 179 | Allogene Therapeutics Inc | ALLO | 0.05% | 20.28K | $42.6K |
| 180 | CytomX Therapeutics Inc | CTMX | 0.05% | 12.80K | $42.1K |
| 181 | Zevra Therapeutics Inc | ZVRA | 0.05% | 3.49K | $41.4K |
| 182 | Phathom Pharmaceuticals Inc | PHAT | 0.04% | 4.68K | $40.3K |
| 183 | Ironwood Pharmaceuticals Inc | IRWD | 0.04% | 9.68K | $40.1K |
| 184 | Tectonic Therapeutic Inc | TECX | 0.04% | 1.10K | $39.7K |
| 185 | Invesco Government & Agency Portfolio | AGPXX | 0.04% | 38.44K | $38.4K |
| 186 | CorMedix Inc | CRMD | 0.04% | 4.61K | $37.9K |
| 187 | OmniAb Inc | OABI | 0.04% | 8.44K | $36.3K |
| 188 | Sagimet Biosciences Inc | SGMT | 0.04% | 3.56K | $36.3K |
| 189 | Silence Therapeutics PLC | SLN | 0.04% | 2.74K | $36.1K |
| 190 | Neurogene Inc | NGNE | 0.04% | 931 | $35.4K |
| 191 | Prime Medicine Inc | PRME | 0.04% | 10.61K | $34.4K |
| 192 | Arvinas Inc | ARVN | 0.04% | 3.76K | $34.0K |
| 193 | Altimmune Inc | ALT | 0.04% | 11.44K | $33.8K |
| 194 | REGENXBIO Inc | RGNX | 0.04% | 3.04K | $33.6K |
| 195 | Aquestive Therapeutics Inc | AQST | 0.04% | 7.31K | $32.9K |
| 196 | ARS Pharmaceuticals Inc | SPRY | 0.04% | 5.84K | $32.2K |
| 197 | Evolus Inc | EOLS | 0.03% | 3.83K | $32.0K |
| 198 | Contineum Therapeutics Inc | CTNM | 0.03% | 1.94K | $31.0K |
| 199 | Cabaletta Bio Inc | CABA | 0.03% | 9.49K | $30.3K |
| 200 | Kyverna Therapeutics Inc | KYTX | 0.03% | 3.54K | $28.8K |
| 201 | Autolus Therapeutics PLC | AUTL | 0.03% | 11.69K | $28.7K |
| 202 | Prothena Corp PLC | PRTA | 0.03% | 3.05K | $27.5K |
| 203 | Puma Biotechnology Inc | PBYI | 0.03% | 2.97K | $27.1K |
| 204 | Kamada Ltd | KMDA | 0.03% | 3.35K | $26.9K |
| 205 | EyePoint Inc | EYPT | 0.03% | 4.92K | $26.6K |
| 206 | Editas Medicine Inc | EDIT | 0.03% | 8.93K | $26.3K |
| 207 | C4 Therapeutics Inc | CCCC | 0.03% | 6.43K | $25.9K |
| 208 | BioAge Labs Inc | BIOA | 0.03% | 2.61K | $25.3K |
| 209 | Larimar Therapeutics Inc | LRMR | 0.03% | 6.06K | $25.2K |
| 210 | Atea Pharmaceuticals Inc | AVIR | 0.03% | 4.65K | $24.9K |
| 211 | Lakefront Biotherapeutics NV | GLPGF | 0.03% | 872 | $24.7K |
| 212 | Foghorn Therapeutics Inc | FHTX | 0.03% | 3.41K | $23.9K |
| 213 | Lexeo Therapeutics Inc | LXEO | 0.03% | 4.57K | $23.1K |
| 214 | Enanta Pharmaceuticals Inc | ENTA | 0.02% | 1.70K | $22.4K |
| 215 | Pacific Biosciences of California Inc | PACB | 0.02% | 18.09K | $22.2K |
| 216 | Rocket Pharmaceuticals Inc | RCKT | 0.02% | 6.36K | $22.1K |
| 217 | Alpha Teknova Inc | TKNO | 0.02% | 3.11K | $21.8K |
| 218 | Upstream Bio Inc | UPB | 0.02% | 3.15K | $21.6K |
| 219 | Lyell Immunopharma Inc | LYEL | 0.02% | 1.35K | $20.7K |
| 220 | Immuneering Corp | IMRX | 0.02% | 3.77K | $19.8K |
| 221 | Orchestra BioMed Holdings Inc | OBIO | 0.02% | 3.50K | $19.0K |
| 222 | Vanda Pharmaceuticals Inc | VNDA | 0.02% | 3.51K | $18.9K |
| 223 | Arcturus Therapeutics Holdings Inc | ARCT | 0.02% | 1.64K | $18.0K |
| 224 | Entrada Therapeutics Inc | TRDA | 0.02% | 2.26K | $17.2K |
| 225 | Anavex Life Sciences Corp | AVXL | 0.02% | 5.39K | $16.9K |
| 226 | Neumora Therapeutics Inc | NMRA | 0.02% | 10.78K | $16.3K |
| 227 | Invivyd Inc | ADGI | 0.02% | 17.14K | $16.3K |
| 228 | AC Immune SA | ACIU | 0.02% | 5.92K | $15.6K |
| 229 | Fulcrum Therapeutics Inc | FULC | 0.02% | 3.87K | $14.9K |
| 230 | Sionna Therapeutics Inc | SION | 0.02% | 2.65K | $14.6K |
| 231 | Keros Therapeutics Inc | KROS | 0.01% | 1.17K | $12.8K |
| 232 | NovaBridge Biosciences | IMAB | 0.01% | 6.55K | $12.5K |
| 233 | SIGA Technologies Inc | SIGA | 0.01% | 4.16K | $12.4K |
| 234 | PepGen Inc | PEPG | 0.01% | 4.03K | $12.2K |
| 235 | Coherus Oncology Inc | CHRS | 0.01% | 8.97K | $11.8K |
| 236 | Voyager Therapeutics Inc | VYGR | 0.01% | 3.52K | $11.7K |
| 237 | Bicycle Therapeutics PLC | BCYC | 0.01% | 2.73K | $11.6K |
| 238 | Pyxis Oncology Inc | PYXS | 0.01% | 3.67K | $11.5K |
| 239 | USD Pending Dividends | — | 0.01% | 0 | $11.2K |
| 240 | Lifecore Biomedical Inc | LNDC | 0.01% | 2.20K | $9.9K |
| 241 | Jyong Biotech Ltd | MENS | 0.01% | 4.42K | $9.5K |
| 242 | Caribou Biosciences Inc | CRBU | 0.01% | 5.79K | $9.3K |
| 243 | Quantum-Si Inc | QSI | 0.01% | 11.51K | $9.0K |
| 244 | CASH & EQUIVALENTS | — | 0.01% | 8.97K | $9.0K |
| 245 | Humacyte Inc | HUMA | 0.01% | 12.90K | $8.8K |
| 246 | Tenaya Therapeutics Inc | TNYA | 0.01% | 12.62K | $8.7K |
| 247 | LENZ Therapeutics Inc | LENZ | 0.01% | 1.82K | $8.5K |
| 248 | Codexis Inc | CDXS | 0.01% | 5.30K | $8.4K |
| 249 | Aardvark Therapeutics Inc | AARD | 0.01% | 1.27K | $7.5K |
| 250 | Black Diamond Therapeutics Inc | BDTX | 0.01% | 3.33K | $7.2K |
| 251 | Rani Therapeutics Holdings Inc | RANI | 0.01% | 6.55K | $5.6K |
| 252 | Gossamer Bio Inc | GOSS | 0.00% | 13.65K | $2.1K |
| 253 | Cartesian Therapeutics Inc 12/31/2050 | — | 0.00% | 2.63K | $359.22 |
| 254 | SECURITIES LENDING - BNYM | — | 0.00% | 1 | $0.01 |
| 255 | Eli Lilly & Co | — | 0.00% | 6.34K | $0.00 |
| 256 | Esperion Therapeutics Inc 03/15/2028 | — | 0.00% | 13.22K | $0.00 |
| 257 | OmniAb Inc 11/02/2027 | — | 0.00% | 125 | $0.00 |
| 258 | Third Harmonic Bio Inc | THRD | 0.00% | 1.60K | $0.00 |
| 259 | Novo Nordisk A/S 06/30/2031 | — | 0.00% | 3.79K | $0.00 |
| 260 | OmniAb Inc 11/02/2027 | — | 0.00% | 125 | $0.00 |
Auf einen Ticker klicken, um alle ETFs anzuzeigen, die ihn halten.
Sektorgewichtung
Geografisches Exposure
Ländergewichtungen gemäß Angaben des Datenanbieters. Die Einstufung als Industrieland/Schwellenland/Frontier-Markt folgt der Klassifikation auf der Methodikseite. Währungsgesichert: Kein Währungshedging im Fondsnamen angegeben.
Ausschüttungen
| Rendite (TTM) | 0.70% | Ausgeschüttet (letzte 12 Monate) | $0.2567 |
| Frequenz | Quarterly | SEC-Rendite | Von unserer Datenquelle nicht bereitgestellt – siehe Emittentenseite |
| Letztes Ex-Datum | Jun 22, 2026 | Letzte Ausschüttung | $0.0342 (Jun 26, 2026) |
| Wachstum 1J | +16.55% | Wachstum 3J / 5J (ann.) | +16.34% / — |
| Ex-Datum | Stichtag | Zahltag | Betrag |
|---|---|---|---|
| Jun 22, 2026 | Jun 22, 2026 | Jun 26, 2026 | $0.0342 |
| Mar 23, 2026 | Mar 23, 2026 | Mar 27, 2026 | $0.0361 |
| Dec 22, 2025 | Dec 22, 2025 | Dec 26, 2025 | $0.0906 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 26, 2025 | $0.0958 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 27, 2025 | $0.0287 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 28, 2025 | $0.0402 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 27, 2024 | $0.0619 |
| Sep 23, 2024 | Sep 23, 2024 | Sep 27, 2024 | $0.0894 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 28, 2024 | $0.0506 |
| Mar 18, 2024 | Mar 19, 2024 | Mar 22, 2024 | $0.0435 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 22, 2023 | $0.0526 |
| Sep 18, 2023 | Sep 19, 2023 | Sep 22, 2023 | $0.0412 |
Nachlaufende Ausschüttungsrendite = Ausschüttungen der letzten 12 Monate ÷ aktueller Kurs. Dies ist NICHT die SEC-30-Tage-Rendite, und künftige Ausschüttungen sind nicht garantiert. Der Unterschied erklärt →
Risikokennzahlen
| Volatilität 1J / 3J | 21.25% / 20.66% | Sharpe 1J / 3J | 2.69 / 1.04 |
| Maximaler Drawdown 1J / 3J | -8.35% / -23.71% | Sortino 1J | 4.46 |
| Beta gegenüber S&P 500 (3J) | 0.746 | Korrelation vs. S&P 500 (1J) | 0.42 |
| Abwärtsabweichung 1J | 12.80% | Verwendeter risikofreier Zinssatz | 3.71% (3M T-bill, FRED) |
Berechnet von ETF Explorer Berechnet aus täglichen dividendenbereinigten Schlusskursen; Volatilität und Drawdown sind annualisierte Werte bzw. Periodenwerte; S&P-500-Exposure wird durch SPY approximiert. Stand Aug 27, 2026. Formeln →
Liquidität
| Heutiges Volumen | 21.57K | Durchschnittliches Volumen | 24.80K |
| AUM | $95.8M | Aufgeld/Abschlag | -0.38% |
| Geld-/Briefspanne | Von unserer Datenquelle nicht bereitgestellt. Prüfen Sie den Kursbildschirm Ihres Brokers; die Spreads sind zur Eröffnung und zum Börsenschluss am weitesten. | ||
Aufgeld/Abschlag vergleicht den verzögerten Marktpreis mit dem zuletzt gemeldeten NAV – ein Richtwert, kein offizielles Schlussaufgeld/-abschlag. So funktioniert die ETF-Liquidität →
Fondsflüsse (geschätzt)
| Zeitraum | Gesch. Nettomittelfluss | % des anfänglichen AUM | AUM Anfang → Ende |
|---|---|---|---|
| 1 Tag | $1.7M | +1.82% | $94.1M → $95.8M |
| 1 Woche | $11.4M | +13.83% | $82.6M → $95.8M |
ETF-Explorer-Schätzung: Veränderung des gemeldeten AUM abzüglich des Marktbewegungseffekts, basierend auf unseren eigenen täglichen Momentaufnahmen. Keine offiziellen Ausgabe-/Rücknahmezahlen des Emittenten.
Offizielle Fondsressourcen
Offizielle Fondsseite ↗
ETF-Emittenten-Website (Invesco) ↗
Prospekteinreichungen (SEC EDGAR) ↗
Jahres-/Halbjahresberichte (SEC EDGAR) ↗
Alle SEC-Einreichungen ↗
Externe Links öffnen die Website des Emittenten oder SEC EDGAR in einem neuen Tab. Der Prospekt und die offiziellen Dokumente sind stets die maßgebliche Quelle — lesen Sie diese vor einer Anlage sorgfältig.
Aktuelle Nachrichten zu IBBQ
In den letzten 7 Tagen erwähnt kein Artikel diesen Fonds direkt – es wird allgemeine ETF-Berichterstattung angezeigt.
US weighs a new round of tariffs on semiconductors, Politico reports ↗
The Trump administration is considering a new round of sweeping tariffs on semiconductors, Politico reported on Thursday citing eight people…
Reuters · Aug 27, 05:28 UTC
Are We Misreading The Oil Demand Shock From Hormuz? ↗
Shortly after the US and Israeli strikes on Iran, a consensus formed: It was widely thought that, after a short war and a sharp spike, the cost of a…
Forbes · Aug 27, 05:25 UTC
How $500,000 in These 2 ETFs Pays $16,560 a Year With a Built-In Inflation Hedge ↗
Most investors reach for TIPS or commodities when inflation starts eroding their savings, but two overlooked asset classes have quietly outpaced…
24/7 Wall Street · Aug 27, 05:21 UTC
Luxxfolio Announces 228-Miner Expansion of Litecoin Mining Operations ↗
Deployment increases the operating fleet by 380% Vancouver, British Columbia--(Newsfile Corp. - August 27, 2026) - Luxxfolio Holdings Inc. (CSE…
Newsfile Corp · Aug 27, 05:00 UTC
Alcohol became a flashpoint in the US-Canada trade war. Now both sides say they're losing. ↗
The US-Canada trade war escalated on Saturday with new 50% tariffs on Canadian alcohol. American booze was pulled from Canadian shelves last year and…
Business Insider · Aug 27, 04:11 UTC
Stock Market: Will S&P 500 Open Up or Down Today? ↗
U.S. stock futures are trending higher early Thursday as Wall Street processes Nvidia Corp.‘s (NASDAQ:NVDA) highly anticipated earnings, strong…
Benzinga · Aug 27, 02:45 UTC
Alle Nachrichten zu IBBQ →
Erklärung: AUM ist das Fondsvermögen. Die Kostenquote (Expense Ratio) ist der jährliche Kostensatz, der bereits in der Rendite berücksichtigt ist. Der NAV ist der Wert des Fondsvermögens je Anteil; der Marktpreis kann leicht darüber (Aufgeld) oder darunter (Abgeld) liegen. Die Gesamtrendite setzt voraus, dass Ausschüttungen reinvestiert wurden. Jeder Datensatz zeigt sein eigenes Stichtagsdatum, da Bestände, Vermögen und Kurse nach unterschiedlichen Zeitplänen aktualisiert werden.